Physician profile
Richard Haskell
NPI 1992794465
$1,115.88
in general payments reported to CMS, 2019-2025
14 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.91 · 2020: $63.65 · 2021: $60.20 · 2022: $365 · 2023: $141 · 2024: $143 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $329.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $317.89 | 2023-2025 | |
| Medtronic, INC. | $94.14 | 2021-2025 | Micra, Attain Command + Surevalve, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $68.62 | 2022-2025 | Gallant, Jot Dx |
| Janssen Pharmaceuticals, INC | $63.76 | 2020-2021 | |
| Cardiovascular Systems INC. | $45.71 | 2020 | |
| Atricure, INC. | $38.50 | 2024 | |
| Medtronic Vascular, INC. | $28.85 | 2019 | |
| Amgen INC. | $28.67 | 2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $24.68 | 2023 | Verquvo |
| Altathera Pharmaceuticals LLC | $20.52 | 2025 | Sotalol Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $20.51 | 2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $19.06 | 2019 | |
| Boston Scientific Corporation | $15.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Haskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.